
Stephanie A Irving, Mhs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1166936/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021. Morbidity and Mortality Weekly Report, 2022, 71, 26-30.	9.0	143
2	Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. Morbidity and Mortality Weekly Report, 2022, 71, 139-145.	9.0	349
3	Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. Morbidity and Mortality Weekly Report, 2022, 71, 255-263.	9.0	350
4	A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016. Vaccine, 2022, 40, 1246-1246.	1.7	0
5	Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021. American Journal of Transplantation, 2022, 22, 306-314.	2.6	11
6	Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022. Morbidity and Mortality Weekly Report, 2022, 71, 352-358.	9.0	148
7	Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022. Morbidity and Mortality Weekly Report. 2022. 71. 495-502.	9.0	35
8	Receipt of COVID-19 Booster Dose Among Fully Vaccinated Pregnant Individuals Aged 18 to 49 Years by Key Demographics. JAMA - Journal of the American Medical Association, 2022, , .	3.8	9
9	Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022. Morbidity and Mortality Weekly Report, 2022, 71, 931-939.	9.0	92
10	Developing algorithms for identifying major structural birth defects using automated electronic health data. Pharmacoepidemiology and Drug Safety, 2021, 30, 266-274.	0.9	11
11	Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110212.	1.0	20
12	Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine, 2021, 39, 3614-3620.	1.7	5
13	COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 8, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 895-899.	9.0	146
14	Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. New England Journal of Medicine, 2021, 385, 1355-1371.	13.9	353
15	Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1539-1544.	9.0	88
16	Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1553-1559.	9.0	146
17	A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010–2016. Vaccine, 2021, , .	1.7	3
18	Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. Vaccine, 2020, 38, 5880-5884.	1.7	11

#	Article	IF	CITATIONS
19	Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine, 2019, 37, 6648-6655.	1.7	24
20	Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15. Vaccine, 2019, 37, 6673-6681.	1.7	39
21	Incidence of Herpes Zoster Among Children: 2003–2014. Pediatrics, 2019, 144, .	1.0	60
22	Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016. Clinical Infectious Diseases, 2019, 68, 1444-1453.	2.9	126
23	Estimating Vaccine Effectiveness Against Hospitalized Influenza During Pregnancy: Multicountry Protocol for a Retrospective Cohort Study. JMIR Research Protocols, 2019, 8, e11333.	0.5	10
24	2015–2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States. Clinical Infectious Diseases, 2018, 66, 665-672.	2.9	52
25	Human Papillomavirus Vaccine Coverage and Prevalence of Missed Opportunities for Vaccination in an Integrated Healthcare System. Academic Pediatrics, 2018, 18, S85-S92.	1.0	14
26	Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine, 2018, 36, 6111-6116.	1.7	24
27	Predictors of Breastfeeding Initiation and Maintenance in an Integrated Healthcare Setting. Journal of Human Lactation, 2017, 33, 256-266.	0.8	23
28	Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. Vaccine, 2017, 35, 5314-5322.	1.7	79
29	The NextGen Study: patient motivation for participation in genome sequencing for carrier status. Molecular Genetics & Genomic Medicine, 2017, 5, 508-515.	0.6	20
30	Implementing a Multipartner HPV Vaccination Assessment and Feedback Intervention in an Integrated Health System. Journal of Public Health Management and Practice, 2017, 23, 589-592.	0.7	11
31	A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation. Genetics in Medicine, 2016, 18, 1258-1268.	1.1	89
32	Risk of anaphylaxis after vaccination in children and adults. Journal of Allergy and Clinical Immunology, 2016, 137, 868-878.	1.5	298
33	Factors Associated with Seasonal Influenza Vaccination in Pregnant Women. Journal of Women's Health, 2015, 24, 394-402.	1.5	52
34	Severity of influenza and noninfluenza acute respiratory illness among pregnant women, 2010–2012. American Journal of Obstetrics and Gynecology, 2015, 212, 202.e1-202.e11.	0.7	22
35	The Association Between Influenza Vaccination and Other Preventative Health Behaviors in a Cohort of Pregnant Women. Health Education and Behavior, 2015, 42, 402-408.	1.3	17
36	Effectiveness of Seasonal Trivalent Influenza Vaccine for Preventing Influenza Virus Illness Among Pregnant Women: A Population-Based Case-Control Study During the 2010–2011 and 2011–2012 Influenza Seasons. Clinical Infectious Diseases, 2014, 58, 449-457.	2.9	134

Stephanie A Irving, Mhs

#	Article	IF	CITATIONS
37	Reply to Fedson. Journal of Infectious Diseases, 2014, 209, 1301-1302.	1.9	1
38	Vaccinations Given During Pregnancy, 2002–2009. American Journal of Preventive Medicine, 2014, 46, 150-157.	1.6	18
39	Safety of influenza vaccination during pregnancy: A review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine, 2014, 32, 3122-3127.	1.7	50
40	Risk of Intussusception after Monovalent Rotavirus Vaccination. New England Journal of Medicine, 2014, 370, 513-519.	13.9	201
41	Comparison of Laboratory-Confirmed Influenza and Noninfluenza Acute Respiratory Illness in Healthcare Personnel during the 2010–2011 Influenza Season. Infection Control and Hospital Epidemiology, 2014, 35, 538-546.	1.0	17
42	Evaluation of obesity as an independent risk factor for medically attended laboratory onfirmed influenza. Influenza and Other Respiratory Viruses, 2013, 7, 160-167.	1.5	24
43	Identifying pregnancy episodes, outcomes, and mother–infant pairs in the Vaccine Safety Datalink. Vaccine, 2013, 31, 2898-2903.	1.7	70
44	Uptake, Coverage, and Completion of Quadrivalent Human Papillomavirus Vaccine in the Vaccine Safety Datalink, July 2006–June 2011. Journal of Adolescent Health, 2013, 53, 637-641.	1.2	16
45	Trivalent Inactivated Influenza Vaccine and Spontaneous Abortion. Obstetrics and Gynecology, 2013, 121, 159-165.	1.2	76
46	Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010–2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010–2011 Influenza Season. Journal of Infectious Diseases, 2013, 207, 1262-1269.	1.9	24
47	Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007–2010. Pharmacoepidemiology and Drug Safety, 2013, 22, 335-344.	0.9	17
48	Predictors of Seasonal Influenza Vaccination During Pregnancy. Obstetrics and Gynecology, 2013, 121, 741-749.	1.2	65
49	Elementary School-Based Influenza Vaccination: Evaluating Impact on Respiratory Illness Absenteeism and Laboratory-Confirmed Influenza. PLoS ONE, 2013, 8, e72243.	1.1	16
50	Comparison of Nasal and Nasopharyngeal Swabs for Influenza Detection in Adults. Clinical Medicine and Research, 2012, 10, 215-218.	0.4	58
51	Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004–2005 through 2007–2008. Influenza and Other Respiratory Viruses, 2012, 6, 37-43.	1.5	91
52	Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000–2010. Influenza and Other Respiratory Viruses, 2012, 6, e143-51.	1.5	13
53	H1N1 and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink Project. American Journal of Preventive Medicine, 2011, 41, 121-128.	1.6	122
54	Comparison of influenza vaccine effectiveness using different methods of case detection: Clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Vaccine, 2011, 29, 387-390.	1.7	21

#	Article	IF	CITATIONS
55	Influenza vaccine effectiveness in Wisconsin during the 2007–08 season: Comparison of interim and final results. Vaccine, 2011, 29, 6558-6563.	1.7	81
56	Real-Time Surveillance to Assess Risk of Intussusception and Other Adverse Events After Pentavalent, Bovine-Derived Rotavirus Vaccine. Pediatric Infectious Disease Journal, 2010, 29, 1-5.	1.1	185
57	Clinical Characteristics and 30-Day Outcomes for Influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) Infections. JAMA - Journal of the American Medical Association, 2010, 304, 1091.	3.8	133
58	Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine, 2009, 27, 6546-6549.	1.7	154
59	Vaccine Risk Communication Interventions in the United States, 1996-2006: A Review. Current Pediatric Reviews, 2007, 3, 238-247.	0.4	0